No Data
Private Companies Are North China Pharmaceutical Company.Ltd's (SHSE:600812) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥583m Last Week
Huabei Pharmaceutical: 2024 Annual Results Advance Announcement
2024 Annual Results Advance Notice
North China Pharmaceutical (600812.SH): Net profit is expected to increase by about 2456.08% in 2024.
On January 16, Gelonghui announced that North China Pharmaceutical (600812.SH) released its 2024 annual performance forecast. According to preliminary calculations by the financial department, it is expected that the net income attributable to the parent company owners will be around 125 million yuan in 2024, an increase of approximately 2,456.08% year-on-year; it is expected that the net income attributable to the parent company owners after deducting non-recurring gains and losses will be around 107 million yuan, which will increase by approximately 152.2326 million yuan compared to the same period last year. The main reasons for this performance forecast increase are: (1) Impact of main business. During the reporting period,
North China Pharmaceutical Withdraws Drug Registration for Antibiotic
North China Pharmaceutical (600812.SH): Withdraw the application for the registration of injectable polymyxin B sulfate pharmaceutical.
On December 16, Gelonghui reported that North China Pharmaceutical (600812.SH) announced that its wholly-owned subsidiary, Shenzhen Huayao Southern Pharmaceutical Co., Ltd. (referred to as "Southern Company"), submitted an application for the market approval of injectable colistin sulfate to the National Medical Products Administration in January 2024 and it has been accepted. Due to the need for further improvement of the pharmaceutical research submission materials for injectable colistin sulfate, Southern Company submitted a request to withdraw the registration of injectable colistin sulfate to the National Medical Products Administration. Recently, Southern Company received the "Notice of Termination of Drug Registration Application" for injectable colistin sulfate issued by the National Medical Products Administration.
North China Pharmaceutical Company.Ltd (SHSE:600812) Not Doing Enough For Some Investors As Its Shares Slump 28%
